Showing results (281-290 of 306) with videos related to

Sort By:
Pageof 31
Lancet (London, England)|November 28, 2022
Pregnancy outcomes after first-trimester treatment with artemisinin derivatives versus non-artemisinin antimalarials: a systematic review and individual patient data meta-analysisMakoto Saito, Rose McGready, Halidou Tinto, et al.
Lancet (London, England)|February 4, 2024
Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trialMehreen S Datoo, Alassane Dicko, Halidou Tinto, et al.
Global Heart|March 18, 2017
Regional and Sex Differences in the Prevalence and Awareness of Hypertension: An H3Africa AWI-Gen Study Across 6 Sites in Sub-Saharan AfricaF Xavier Gómez-Olivé, Stuart A Ali, Felix Made, et al.
Malaria Journal|December 2, 2025
Efficacy of artemether-lumefantrine, dihydroartemisinin-piperaquine, and artesunate-pyronaridine for the treatment of uncomplicated Plasmodium falciparum malaria in Burkina Faso, 2020-2021Adama Gansane, Casimir Tarama, Moussa Lingani, et al.
Journal of Clinical Pharmacology|September 30, 2024
Pharmacokinetics of Ganaplacide and Lumefantrine in Adults, Adolescents, and Children with Plasmodium falciparum Malaria Treated with Ganaplacide Plus Lumefantrine Solid Dispersion Formulation: Analysis of Data from a Multinational Phase 2 StudyRamachandra Sangana, Bernhards Ogutu, Adoke Yeka, et al.
BMJ Open|December 23, 2016
Maternal Malaria and Malnutrition (M3) initiative, a pooled birth cohort of 13 pregnancy studies in Africa and the Western PacificHolger W Unger, Jordan E Cates, Julie Gutman, et al.
The Lancet. Infectious Diseases|June 16, 2023
Ganaplacide (KAF156) plus lumefantrine solid dispersion formulation combination for uncomplicated Plasmodium falciparum malaria: an open-label, multicentre, parallel-group, randomised, controlled, phase 2 trialBernhards Ogutu, Adoke Yeka, Sylvia Kusemererwa, et al.
Scientific Reports|June 26, 2023
Fetal sex and risk of pregnancy-associated malaria in Plasmodium falciparum-endemic regions: a meta-analysisHolger W Unger, Anastasia Jessica Hadiprodjo, Julie R Gutman, et al.
The Lancet. Infectious Diseases|February 11, 2024
The public health impact and cost-effectiveness of the R21/Matrix-M malaria vaccine: a mathematical modelling studyNora Schmit, Hillary M Topazian, H Magloire Natama, et al.
Lancet (London, England)|May 8, 2021
Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trialMehreen S Datoo, Magloire H Natama, Athanase Somé, et al.
Pageof 31